Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Future directions in prostate cancer from the PROTEUS trial

Mary-Ellen Taplin • 29 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer Apalutamide
PROTEUS

Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute, Boston, MA, provides insight into a sub study of the PROTEUS trial (NCT03767244) in which patients were randomized to proceed straight to surgery or receive neoadjuvant apalutamide and androgen-deprivation therapy. Prof. Taplin highlights ongoing biomarker work examining markers of response and resistance to inform future trials. In addition, future work will need to validate that the results found in the PROTEUS trial correlate with long-term endpoints including failure-free survival and progression-free survival. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mary-Ellen Taplin

Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
PROTEUS: apalutamide plus ADT in high-risk localized prostate cancer
2:43
PROTEUS: apalutamide plus ADT in high-risk localized prostate cancer
Mary-Ellen Taplin • 29 May 2026

Related Videos

Improving emotional health assessment in patients with kidney cancer
0:57
Improving emotional health assessment in patients with kidney cancer
Eric Jonasch • 30 May 2026
Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026
The content of VJOncology is intended for healthcare professionals